The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting.
Notes
Cites: Lancet. 2002 Jun 22;359(9324):2131-912090977
Cites: Cancer. 2003 Nov 1;98(9):1802-1014584060
Cites: N Engl J Med. 2003 Nov 6;349(19):1793-80214551341
Cites: Int J Cancer. 1999 Sep 9;82(6):893-90010446459
Cites: J Clin Oncol. 1996 Feb;14(2):422-88636752
Cites: N Engl J Med. 1997 Oct 2;337(14):949-559395428
Cites: N Engl J Med. 1997 Oct 2;337(14):956-629309100
Cites: N Engl J Med. 2004 Mar 11;350(11):1081-9215014181